High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France
Domaines
Psychiatrie et santé mentaleOrigine | Fichiers éditeurs autorisés sur une archive ouverte |
---|